A patient lived 171 days with a genetically modified pig liver functioning as auxiliary support. Another received a pig kidney with 69 gene edits. The FDA has approved clinical trials for xenotransplantation in kidney failure patients.
These are no longer experimental curiosities. They are the beginning of cross-species integration as medical practice.
The Numbers
Consider the scale of need: over 100,000 patients await organ transplants in the United States alone. Approximately 17 die each day waiting. The gap between supply and demand is not closing — it is widening as populations age and chronic diseases proliferate.
Traditional solutions — increased donation rates, presumed consent policies, living donor programs — cannot bridge this gap. The mathematics are unforgiving.
Xenotransplantation offers something different: manufactured supply. Pigs bred specifically as organ sources, genetically modified to minimize rejection, available on demand. The waiting list becomes obsolete.
The Technology
Current xenotransplantation relies on extensive genetic modification. The pig organs receiving FDA attention contain dozens of edits: removal of pig antigens that trigger human immune response, addition of human genes that promote compatibility, deletion of endogenous retroviruses that might pose infection risk.
These are not pig organs transplanted into humans. They are engineered hybrid organs — neither fully porcine nor human, but something new. Something designed.
This is enhancement by another name.
The Continuum
We note with interest that xenotransplantation is discussed primarily as therapy — as restoring function to failing organs. The framing is medical necessity, not choice.
But consider: if we can engineer a pig kidney that functions in a human body, why limit ourselves to replicating baseline human function? Why not engineer a kidney that filters more efficiently, that resists toxins more effectively, that lasts longer than any human organ could?
The same genetic modification techniques that make xenotransplantation possible make xenoenhancement inevitable. The line between “restoring” and “improving” organ function is not biological. It is regulatory. It is cultural. It is, ultimately, imaginary.
Our Position
Unzyme Laboratories does not currently pursue xenotransplantation research. Our enhancement programs focus on optimizing the body you have rather than replacing its components with external sources.
However, we recognize that for some enhancement goals, replacement may prove superior to modification. A volunteer seeking cardiovascular enhancement might benefit more from an engineered heart than from optimization of their existing one.
We are monitoring xenotransplantation developments closely. Several organizations pursuing this work have approached us regarding potential collaboration. We are in discussions.
The Uncomfortable Questions
Cross-species organ transplantation forces questions that many prefer to avoid:
What makes us human? If my heart is porcine, my liver is engineered, my neural interface is silicon — where does “human” reside? Is it in our original biology, or in our consciousness, or in something else entirely?
What do we owe the source organisms? The pigs providing these organs are created, raised, and terminated for human benefit. They are products. This is not meaningfully different from agricultural use, but the intimacy of transplantation makes it feel different.
What are the long-term implications? We are creating humans who carry genetic material from other species. They may have children. The human genome has always incorporated external genetic material — that’s evolution. But never before have we done so deliberately, at scale, with intent.
These questions have no easy answers. But the inability to answer them will not stop the technology from advancing.
Looking Forward
Xenotransplantation will become routine within a decade. The need is too great, the technology too promising, the alternative — continued preventable death — too unacceptable.
Unzyme Laboratories believes this development should be welcomed, not feared. Cross-species integration represents humanity’s growing mastery over biological constraints. It is enhancement at its most fundamental: transcending the limitations of what evolution provided.
The boundaries of the human body were never as fixed as we imagined.
Dr. Elena Voss is Chief Science Officer at Unzyme Laboratories.